Matica Biotechnology Partners with NCTM to Launch End-to-End CGT Manufacturing Platform

• Matica Biotechnology has partnered with the National Center for Therapeutics Manufacturing to offer a full-service platform for cell and gene therapy development and manufacturing.

• The collaboration combines early-stage research with commercial-scale production, based in College Station, Texas.

Matica Biotechnology, a CDMO specialising in cell and gene therapies (CGT), has announced a strategic partnership with the National Center for Therapeutics Manufacturing (NCTM), part of the Texas A&M Engineering Experiment Station. The alliance is intended to provide an integrated service offering for CGT innovators—from research to commercialisation.

The partnership, unveiled this week, brings together NCTM’s early-phase development expertise and Matica’s regulatory and manufacturing capabilities. Both facilities are located in College Station, Texas, enabling the collaboration to function as a local, end-to-end resource hub for therapy developers.

The collaboration aims to streamline the CGT development process, reduce time-to-market, and lower production costs. Matica’s facility includes advanced systems such as Ambr®250 and the single-use MatiMax cell line, designed to increase efficiency and accelerate clinical progress.

NCTM contributes with its bench-to-pilot scale bioprocessing infrastructure and a blend of academic and industrial experience. It supports academic researchers, biotech start-ups, and translational projects in the early discovery stage.

“This partnership creates a unique synergy between academic innovation and industrial execution,” said Paul Kim, Chief Executive Officer of Matica Biotechnology.